Lion TCR announces USD20m from Series A financing round.
M2 PHARMA-May 28, 2018-Lion TCR announces USD20m from Series A financing round
(C)2018 M2 COMMUNICATIONS
Singapore biotech company Lion TCR Pte Ltd reported on Sunday the receipt of USD20m under its Series A financing round.
The Series A financing round was led primarily by undisclosed existing investors as well as other new investors: Yashang Capital and Westlake Ventures Capital.
Proceeds from this fundraising will be used by Lion TCR Pte Ltd to advance its on-going clinical trials of its lead candidate LioCyx (personalized HBV specific TCR T cell therapy against HCC) in major hospitals in China and Singapore, as well as for broadening its products pipeline to fight viral-related solid tumors and clearance of chronic hepatitis B.
Hepatocellular carcinoma (HCC) has over 700,000 new cases every year, the world second deadly cancer, of which 80% in Asia Pacific and 50% in China.
((Comments on this story may be sent to info@m2.com))
 Printer friendly
 Cite/link
 Email
 Feedback
| |
| Publication: | M2 Pharma |
|---|---|
| Date: | May 28, 2018 |
| Words: | 155 |
| Previous Article: | Luye Pharma closes acquisition of signature products Seroquel and Seroquel XR. |
| Next Article: | Indivior updates the regulatory submission of SUBLOCADE Injection for opioid dependence in Australia. |
| Topics: | |